On July 8, JD Health rose 3.04% in regular trading, trading at 37.14 HKD/share, with turnover of approximately 253 million HKD.
On the news front, the Internet & Direct Marketing Retail sector strengthened broadly during the session, with BABA-W surging 12.11%, PA GOODDOCTOR rising 4.85%, and ALI HEALTH gaining 3.99%, driving positive industry-wide sentiment that lifted JD Health in tandem. Meanwhile, UBS recently maintained its Buy rating on JD Health, noting that its online platform has established competitive advantages in both user base and supply chain dimensions. The bank forecasts online pharmacy platform revenue to achieve a double-digit compound annual growth rate from 2025 to 2028, and believes that regulatory tightening since 2022 has had limited practical impact on online purchasing behavior.
Additionally, JD Health has maintained a steady daily share buyback pace of 500,000 shares, signaling management confidence in the company's intrinsic value. The company also recently announced expanded partnerships in AI-powered medical devices and mental health services, reinforcing its growth trajectory.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments